MeTA Process and Progress in Jordan

Post on 22-Jan-2015

1.221 views 3 download

description

A presentation describing how the Medicines Transparency Alliance is set up in Jordan and the work it proposes to do, by Dr Rania Bader, made at the launch of MeTA Jordan in May 2009.

Transcript of MeTA Process and Progress in Jordan

Rania Bader

MeTA Consultant

MeTA Process and Progress in Jordan

MeTA 10/04/23 1

Jordan’s Fact Sheet

• Population: 5.8 million

• Health expenditure: 10.4 % of GDP (30% of this spent on medicines)

• Total Medicine Expenditure $ 338 Million

• Public Medicine Expenditure $ 112.6 Million

• 25% Medicine expenditure (public sector) 75 % Medicine expenditure (private sector)

• Local medicines manufacturers: 16

• Medicines expenditure growth 17% per annum compared to GDP growth of 3.3%

10/04/23MeTA 2

10/04/23MeTA 3

What is MeTA?

MeTA brings together at the international and national levels, a diverse group of people working in the pharmaceutical sector through a (multi-stakeholders approach) to find ways to improve/increase transparency and accountability in selection, regulation, procurement, distribution and use of medicines in countries

MeTA partners are the UK Department for International Development (DFID) , the WHO and the World Bank (WB)

10/04/23MeTA 4

Agenda

A. MeTA Process in Jordan

B. MeTA Progress in Jordan ( achievements so far)

C. Monitoring and Evaluation

D. Challenges

E. Key Successes

F. Getting more information

MeTA Process in Jordan:

1. It started with scoping visits

2. Looked into reasons for Jordan to be one of the MeTA pilot Countries

3. Proposal was sent to the Government

4. The Government approved

5. Formed the MeTA Council / stakeholder

6. Drafting Jordan’s Workplan

7. MOU signed

10/04/23MeTA 5

10/04/23MeTA 6

MeTA in Jordan

MeTA Process in Jordan:

The Minister of Health sent an official letter to MOPIC approving on having the High Health Council (HHC) hosting the MeTA Secretariat

10/04/23MeTA 7

MeTA Process in Jordan:

Jordan’s MeTA Council held its first meeting at the HHC in August 2008 after the MeTA council was formed and endorsed by the MOH, the council representation is from the Government, private sector, civil society organizations, professional organizations, and the academia. In addition non- voting representatives from the World Bank (WB), the World Health Organization (WHO) and Health Action international (HAI), with the presence of the MeTA national consultant in Jordan

10/04/23MeTA 8

MeTA Process in Jordan:

The Council serves as the highest policy making and consultative body

The council elected his chairperson Dr Taher AbuElSamen and also nominated him to participate as Jordan’s representative on the MeTA International Advisory Group (MIAG) in London every year

10/04/23MeTA 9

MeTA Process in Jordan:

The MeTA Council drafted the internal rules and formed Three Committees then developed activities for the areas of work that they chose and included them in the Jordan MeTA workplan

Jordan MeTA workplan has been sent officially to the MMB on the 9th of February 2009 for approval, and it was approved after 7 working days, MOU was signed accordingly

10/04/23MeTA 10

MeTA Process in Jordan:

The three committees that have been formed out of the MeTA Council are:

1- Evidence Based Decision Making for the RDL Committee

2- Encouraging Best Practice and Promote Rational Drug Use Committee

3- Civil Society organizations Building Capacity Committee

10/04/23MeTA 11

MeTA Progress in Jordan

Supply Chain Mapping Private Sector Mapping CSO Mapping NICE Training on Using Health Technology

Assessment to inform decision-making in healthcare

MeTA Chair has Participated in the MIAG meeting Held an important session on medicines and

transparency at the WHA

10/04/23MeTA 12

WHA 62 Geneva 2009

MeTA Jordan held an important session on medicines and transparency and Good Governance at the WHA, Geneva, on19th May. Over 80 participants from the WHA attended with representatives from over 20 different countries including Iraq, Libia,Ghana, Cameroon, Peru, Argentina, India, and Bangladesh

Members of the MeTA Jordan Council presented the work they have done so far in setting up a multi-stakeholder group comprising representatives from Government, the pharmaceutical industry, and civil society organizations

10/04/23MeTA 13

Monitoring and Evaluation

Monthly progress reports of three working committees and MeTA Jordan Secretariat

Quarterly reports by MeTA Council to International MeTA Secretariat Reports will be published on national & international MeTA websites

Financial reporting by national MeTA Secretariat

External monitor from another MeTA pilot country on annual and also the CSO Alliance could be involved in the monitoring and evaluation process

10/04/23MeTA 14

Challenges

Assuring commitment & engagement of ALL stakeholders

Clarity and understanding of MeTA’s objectives to Jordan’s MeTA Council stakeholders at ALL levels of their organisations

Lack of good quality information and data

Civil Society are in early stages of development How to make the MeTA approach SUSTAINABLE The concept behind MeTA processes to be country-led, that

in a way caused the process in Jordan to be slower

10/04/23MeTA 15

Key Successes

The full support from the Jordanian government, MOH and MOPIC

The full support from the international MeTA Secretariat

WHO Jordan Country Representative was very supportive

10/04/23MeTA 16

Key Successes

DFID, WHO/HQ, WB and WHO/EMRO regional office were very supportive

Cooperation between all stakeholders including the private sector and the Council members from all sectors were highly committed to moving the MeTA process forward

10/04/23MeTA 17

10/04/23MeTA 18

References for getting more Information:

http://www.medicinestransparency.org/meta-countries/jordan/ http://www.haiweb.org/medicineprices/surveys/200405JO/survey_report.pdf http://www.medicinestransparency.org/fileadmin/uploads/Documents/WHA-Briefing-

note.pdf http://www.medicinestransparency.org/fileadmin/uploads/Documents/WHA-MeTA-Country-

Jordan.pdf http://www.medicinestransparency.org/fileadmin/uploads/Documents/WHO-HAI-summary-

report.pdf http://www.medicinestransparency.org/news-events/article/view/information-about-

medicines-where-to-start/80/

10/04/23MeTA 19

Thank you!

Rania Bader Email: raniasb2002@yahoo.com Mobile number +962 79 5691921

MeTA: www.MedicinesTransparency.org